Alzheimer's disease: Seeing the signs early

Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia. Data sour...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Academy of Nurse Practitioners 2009-11, Vol.21 (11), p.588-595
1. Verfasser: Leifer, Bennett P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 595
container_issue 11
container_start_page 588
container_title Journal of the American Academy of Nurse Practitioners
container_volume 21
creator Leifer, Bennett P.
description Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia. Data sources: Published literature on case detection, diagnosis, and treatment of AD. Conclusions: There are a number of simple, accurate, and fast tools to facilitate case detection, including the Mini‐Mental State Examination. Once a diagnosis has been made, healthcare providers, patients, and caregivers can evaluate treatment options. Several medications are available for symptomatic treatment of AD, including the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, and for later stage disease, the N‐methyl D‐aspartate (NMDA) receptor antagonist, memantine. Implications for Practice: Early intervention is critical because a delay in treatment is associated with nonreversible symptom progression. Realistic treatment expectations include reduction in symptom severity and slowed decline in cognition, function, and behavior. Treatment may allow patients to retain independence longer and reduce the burden that advanced AD places on caregivers.
doi_str_mv 10.1111/j.1745-7599.2009.00436.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734132195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734132195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4066-6024ab7e4a523d75e02896fdb89eaaff38510f5fb53dc66b7a8b58f5bbbe19833</originalsourceid><addsrcrecordid>eNqNkE1PwkAQhjdGI4j-BdMbB9O6H91u18RDQxQlBI0f8bjZbadQbAG7EMFf79YSvTqXmWTfZyb7IOQRHBBXl_OAiJD7gksZUIxlgHHIomB7gLq_D4duxiHxqRS0g06snWNMOCXkGHWIlBhTirvoIim_ZlBUUPetlxUWtIUr7xmgWEy99Qw8W0wX1gNdl7tTdJTr0sLZvvfQ6-3Ny-DOHz8M7wfJ2E9DHEV-hGmojYBQc8oywQHTWEZ5ZmIJWuc5iznBOc8NZ1kaRUbo2PA458YYIDJmrIf67d5VvfzYgF2rqrAplKVewHJjlWAhYZRI7pJxm0zrpbU15GpVF5Wud4pg1ZhSc9UIUY0Q1ZhSP6bU1qHn-yMbU0H2B-7VuMB1G_gsStj9e7EaJcnETY73W76wa9j-8rp-V5Fggqu3yVA9yZH7MnlUhH0Ddi6EoQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734132195</pqid></control><display><type>article</type><title>Alzheimer's disease: Seeing the signs early</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Leifer, Bennett P.</creator><creatorcontrib>Leifer, Bennett P.</creatorcontrib><description>Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia. Data sources: Published literature on case detection, diagnosis, and treatment of AD. Conclusions: There are a number of simple, accurate, and fast tools to facilitate case detection, including the Mini‐Mental State Examination. Once a diagnosis has been made, healthcare providers, patients, and caregivers can evaluate treatment options. Several medications are available for symptomatic treatment of AD, including the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, and for later stage disease, the N‐methyl D‐aspartate (NMDA) receptor antagonist, memantine. Implications for Practice: Early intervention is critical because a delay in treatment is associated with nonreversible symptom progression. Realistic treatment expectations include reduction in symptom severity and slowed decline in cognition, function, and behavior. Treatment may allow patients to retain independence longer and reduce the burden that advanced AD places on caregivers.</description><identifier>ISSN: 1041-2972</identifier><identifier>EISSN: 1745-7599</identifier><identifier>DOI: 10.1111/j.1745-7599.2009.00436.x</identifier><identifier>PMID: 19900220</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Alzheimer Disease - diagnosis ; Alzheimer Disease - drug therapy ; Alzheimer's disease ; Cholinesterase Inhibitors - therapeutic use ; diagnosis ; Disease Progression ; Galantamine - therapeutic use ; Humans ; Memantine - therapeutic use ; Neuroprotective Agents - therapeutic use ; Nootropic Agents - therapeutic use ; Nursing ; Phenylcarbamates - therapeutic use ; primary care ; Primary Health Care ; Psychometrics ; Rivastigmine ; Time Factors ; treatment</subject><ispartof>Journal of the American Academy of Nurse Practitioners, 2009-11, Vol.21 (11), p.588-595</ispartof><rights>2009 The Author. Journal compilation © 2009 American Academy of Nurse Practitioners</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4066-6024ab7e4a523d75e02896fdb89eaaff38510f5fb53dc66b7a8b58f5bbbe19833</citedby><cites>FETCH-LOGICAL-c4066-6024ab7e4a523d75e02896fdb89eaaff38510f5fb53dc66b7a8b58f5bbbe19833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1745-7599.2009.00436.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1745-7599.2009.00436.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19900220$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leifer, Bennett P.</creatorcontrib><title>Alzheimer's disease: Seeing the signs early</title><title>Journal of the American Academy of Nurse Practitioners</title><addtitle>J Am Acad Nurse Pract</addtitle><description>Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia. Data sources: Published literature on case detection, diagnosis, and treatment of AD. Conclusions: There are a number of simple, accurate, and fast tools to facilitate case detection, including the Mini‐Mental State Examination. Once a diagnosis has been made, healthcare providers, patients, and caregivers can evaluate treatment options. Several medications are available for symptomatic treatment of AD, including the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, and for later stage disease, the N‐methyl D‐aspartate (NMDA) receptor antagonist, memantine. Implications for Practice: Early intervention is critical because a delay in treatment is associated with nonreversible symptom progression. Realistic treatment expectations include reduction in symptom severity and slowed decline in cognition, function, and behavior. Treatment may allow patients to retain independence longer and reduce the burden that advanced AD places on caregivers.</description><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer's disease</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>diagnosis</subject><subject>Disease Progression</subject><subject>Galantamine - therapeutic use</subject><subject>Humans</subject><subject>Memantine - therapeutic use</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Nootropic Agents - therapeutic use</subject><subject>Nursing</subject><subject>Phenylcarbamates - therapeutic use</subject><subject>primary care</subject><subject>Primary Health Care</subject><subject>Psychometrics</subject><subject>Rivastigmine</subject><subject>Time Factors</subject><subject>treatment</subject><issn>1041-2972</issn><issn>1745-7599</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1PwkAQhjdGI4j-BdMbB9O6H91u18RDQxQlBI0f8bjZbadQbAG7EMFf79YSvTqXmWTfZyb7IOQRHBBXl_OAiJD7gksZUIxlgHHIomB7gLq_D4duxiHxqRS0g06snWNMOCXkGHWIlBhTirvoIim_ZlBUUPetlxUWtIUr7xmgWEy99Qw8W0wX1gNdl7tTdJTr0sLZvvfQ6-3Ny-DOHz8M7wfJ2E9DHEV-hGmojYBQc8oywQHTWEZ5ZmIJWuc5iznBOc8NZ1kaRUbo2PA458YYIDJmrIf67d5VvfzYgF2rqrAplKVewHJjlWAhYZRI7pJxm0zrpbU15GpVF5Wud4pg1ZhSc9UIUY0Q1ZhSP6bU1qHn-yMbU0H2B-7VuMB1G_gsStj9e7EaJcnETY73W76wa9j-8rp-V5Fggqu3yVA9yZH7MnlUhH0Ddi6EoQ</recordid><startdate>200911</startdate><enddate>200911</enddate><creator>Leifer, Bennett P.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200911</creationdate><title>Alzheimer's disease: Seeing the signs early</title><author>Leifer, Bennett P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4066-6024ab7e4a523d75e02896fdb89eaaff38510f5fb53dc66b7a8b58f5bbbe19833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer's disease</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>diagnosis</topic><topic>Disease Progression</topic><topic>Galantamine - therapeutic use</topic><topic>Humans</topic><topic>Memantine - therapeutic use</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Nootropic Agents - therapeutic use</topic><topic>Nursing</topic><topic>Phenylcarbamates - therapeutic use</topic><topic>primary care</topic><topic>Primary Health Care</topic><topic>Psychometrics</topic><topic>Rivastigmine</topic><topic>Time Factors</topic><topic>treatment</topic><toplevel>online_resources</toplevel><creatorcontrib>Leifer, Bennett P.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Nurse Practitioners</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leifer, Bennett P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alzheimer's disease: Seeing the signs early</atitle><jtitle>Journal of the American Academy of Nurse Practitioners</jtitle><addtitle>J Am Acad Nurse Pract</addtitle><date>2009-11</date><risdate>2009</risdate><volume>21</volume><issue>11</issue><spage>588</spage><epage>595</epage><pages>588-595</pages><issn>1041-2972</issn><eissn>1745-7599</eissn><abstract>Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia. Data sources: Published literature on case detection, diagnosis, and treatment of AD. Conclusions: There are a number of simple, accurate, and fast tools to facilitate case detection, including the Mini‐Mental State Examination. Once a diagnosis has been made, healthcare providers, patients, and caregivers can evaluate treatment options. Several medications are available for symptomatic treatment of AD, including the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, and for later stage disease, the N‐methyl D‐aspartate (NMDA) receptor antagonist, memantine. Implications for Practice: Early intervention is critical because a delay in treatment is associated with nonreversible symptom progression. Realistic treatment expectations include reduction in symptom severity and slowed decline in cognition, function, and behavior. Treatment may allow patients to retain independence longer and reduce the burden that advanced AD places on caregivers.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19900220</pmid><doi>10.1111/j.1745-7599.2009.00436.x</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1041-2972
ispartof Journal of the American Academy of Nurse Practitioners, 2009-11, Vol.21 (11), p.588-595
issn 1041-2972
1745-7599
language eng
recordid cdi_proquest_miscellaneous_734132195
source Wiley-Blackwell Journals; MEDLINE
subjects Alzheimer Disease - diagnosis
Alzheimer Disease - drug therapy
Alzheimer's disease
Cholinesterase Inhibitors - therapeutic use
diagnosis
Disease Progression
Galantamine - therapeutic use
Humans
Memantine - therapeutic use
Neuroprotective Agents - therapeutic use
Nootropic Agents - therapeutic use
Nursing
Phenylcarbamates - therapeutic use
primary care
Primary Health Care
Psychometrics
Rivastigmine
Time Factors
treatment
title Alzheimer's disease: Seeing the signs early
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T19%3A04%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alzheimer's%20disease:%20Seeing%20the%20signs%20early&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Nurse%20Practitioners&rft.au=Leifer,%20Bennett%20P.&rft.date=2009-11&rft.volume=21&rft.issue=11&rft.spage=588&rft.epage=595&rft.pages=588-595&rft.issn=1041-2972&rft.eissn=1745-7599&rft_id=info:doi/10.1111/j.1745-7599.2009.00436.x&rft_dat=%3Cproquest_cross%3E734132195%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734132195&rft_id=info:pmid/19900220&rfr_iscdi=true